BIOXCEL THERAPEUTICS INC (BTAI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.04-9.04%
Close 2026-10-01 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · BTAI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
In the quarter ended on March 31, the FDA accepted the Company’s supplemental New Drug Application (sNDA) for IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disor…
Stated in 1 of 1 supplied quarters. Management reported: “In the quarter ended on March 31, the FDA accepted the Company’s supplemental New Drug Application (sNDA) for IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia and assigned a PDUFA target action date of November 14, 2026.” “The FDA has assigned a PDUFA target action date of November 14, 2026, which, if approved, would represent the first FDA-approved treatment option for acute agitation associated with bipolar disorders or schizophrenia in the at-home setting.” Revenue was $0.206 million in 2026-Q1.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“In the quarter ended on March 31, the FDA accepted the Company’s supplemental New Drug Application (sNDA) for IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disor…”
Strategic Options · Exploring Value-Maximizing Options: The Company engaged MTS Health Partners as an advisor for evaluation of strategic options to maximize shareholder value and advance the commerc…
Stated in 1 of 1 supplied quarters. Management reported: “Strategic Options · Exploring Value-Maximizing Options: The Company engaged MTS Health Partners as an advisor for evaluation of strategic options to maximize shareholder value and advance the commercial and development plans for IGALMI, which may include, but are not limited to, a sale of the Company, a merger or other business combination, a collaboration, joint venture, royalty or license agreement of all or a portion of our assets, a recapitalization or other financing transaction, or continued execution of our standalone operating plan.”
“Strategic Options · Exploring Value-Maximizing Options: The Company engaged MTS Health Partners as an advisor for evaluation of strategic options to maximize shareholder value and advance the commerc…”
TRANQUILITY Program · TRANQUILITY In-Care Phase 3 Trial : The TRANQUILITY In-Care trial is designed as a double-blind, placebo-controlled study to evaluate the efficacy and safety of a 60 mcg dose of…
Stated in 1 of 1 supplied quarters. Management reported: “TRANQUILITY Program · TRANQUILITY In-Care Phase 3 Trial : The TRANQUILITY In-Care trial is designed as a double-blind, placebo-controlled study to evaluate the efficacy and safety of a 60 mcg dose of BXCL501 for the acute treatment of agitation associated with Alzheimer’s dementia.” “The Company remains focused on BXCL501’s potential in this disease, supported by a favorable regulatory environment following a recent FDA approval in an adjacent indication, which is further reinforcing the need in this therapeutic area.”
“TRANQUILITY Program · TRANQUILITY In-Care Phase 3 Trial : The TRANQUILITY In-Care trial is designed as a double-blind, placebo-controlled study to evaluate the efficacy and safety of a 60 mcg dose of…”
Develop and execute commercial launch plans for IGALMI in the at-home setting following regulatory approval.
Manage financial position including cash, losses, and credit agreement compliance amid operational losses.
Over the trailing year it converted 0.99x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
31 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.